Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Bortezomib
Drug ID BADD_D00284
Description Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma.[A204083] The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib.[L14180] However, multiple mechanisms may be involved in the anticancer activity of bortezomib.[A204083] Bortezomib was first synthesized in 1995.[A204083] In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE.[A204146] Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.[A214307]
Indications and Usage Bortezomib is indicated for the treatment of adult patients with multiple myeloma or mantle cell lymphoma.[L14177]
Marketing Status approved; investigational
ATC Code L01XG01
DrugBank ID DB00188
KEGG ID D03150
MeSH ID D000069286
PubChem ID 387447
TTD Drug ID D0SH3I
NDC Product Code 62158-0011; 65129-1264; 0409-1703; 70710-1411; 51817-586; 68001-541; 14096-140; 0143-9098; 67184-0530; 71288-118; 72205-183; 63323-821; 12502-5268; 42385-716; 55111-922; 63323-721; 68001-534; 48957-0018; 10019-991; 70225-1102; 50742-484; 70511-161; 47848-031; 54893-0011; 66529-0006; 76055-0027; 82920-006; 0409-1704; 70771-1708; 72266-243; 72266-244; 54245-7004; 62207-972; 67184-0026; 60505-6050; 70511-162; 25021-244; 68001-540; 42973-140; 55150-337; 63020-049; 0409-1700; 70860-225; 62756-982; 68554-0051; 78848-009
UNII 69G8BD63PP
Synonyms Bortezomib | LDP-341 | LDP 341 | LDP341 | PS 341 | 341, PS | PS-341 | PS341 | Velcade
Chemical Information
Molecular Formula C19H25BN4O4
CAS Registry Number 179324-69-7
SMILES B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypovolaemia14.05.05.002--Not Available
Hypovolaemic shock24.06.02.0170.000112%Not Available
Hypoxia22.02.02.0030.000392%
Ichthyosis23.01.02.002; 03.05.01.004--Not Available
Ichthyosis acquired23.01.02.001--Not Available
Ileus07.13.01.0010.000336%
Ileus paralytic07.02.05.0010.000504%Not Available
Immune system disorder10.02.01.001--Not Available
Impaired healing08.03.02.001--Not Available
Increased appetite08.01.09.027; 14.03.01.003--Not Available
Infection11.01.08.002--Not Available
Infertility21.03.02.001--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Injection site bruising24.07.06.017; 23.03.11.015; 08.02.03.042; 12.07.03.0420.002093%Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.0010.013028%Not Available
Injection site extravasation12.07.03.002; 08.02.03.0020.000381%Not Available
Injection site haemorrhage24.07.01.010; 12.07.03.005; 08.02.03.005--Not Available
Injection site induration12.07.03.007; 08.02.03.0070.000873%Not Available
Injection site inflammation12.07.03.009; 08.02.03.0080.000381%Not Available
Injection site irritation08.02.03.027; 12.07.03.0270.001198%Not Available
Injection site pain12.07.03.011; 08.02.03.0100.005955%Not Available
Injection site phlebitis24.12.03.003; 12.07.03.012; 08.02.03.011--Not Available
Injection site pruritus08.02.03.013; 23.03.12.007; 12.07.03.0140.002586%Not Available
Injection site rash23.03.13.010; 12.07.03.032; 08.02.03.0320.001903%Not Available
Injection site reaction12.07.03.015; 08.02.03.0140.006559%
Injection site ulcer23.07.03.012; 12.07.03.017; 08.02.03.0160.000112%Not Available
Injection site urticaria10.01.06.003; 08.02.03.029; 23.04.02.003; 12.07.03.0290.001142%Not Available
Injection site vesicles23.03.01.024; 12.07.03.051; 08.02.03.0510.000492%Not Available
Injection site warmth12.07.03.036; 08.02.03.0360.000761%Not Available
Insomnia17.15.03.002; 19.02.01.002--
The 10th Page    First    Pre   10 11 12 13 14    Next   Last    Total 26 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene